文献速递甲状腺与浅表头颈技术与安全US

ACR TIRADS与ATA 2015风险分层系统在偶发甲状腺结节评估中的成本效益比较

Cost-Effectiveness of the ACR TIRADS Compared to the ATA 2015 Risk Stratification Systems in the Evaluation of Incidental Thyroid Nodules.
PubMed 文献 · Acad Radiol · 2024-04-27

该研究采用决策树模型进行成本-效用分析,评估成人偶发甲状腺结节(<4 cm)分别按ATA2015与TIRADS指南管理时的成本效益;基础案例中TIRADS以多获得0.005 QALY且少花费25加元而微弱优势主导ATA2015,概率敏感性分析显示TIRADS在79.7%的情况下更具成本效益。

要点

  • 偶发甲状腺结节<4 cm时,TIRADS策略较ATA2015微弱主导:多0.005 QALY且少25加元。
  • 概率敏感性分析中TIRADS在79.7%的情况下更具成本效益。
  • 结果对活检恶性率和良性/亚临床恶性/监测中患者的效用值敏感。

核心结论

  • 在大多数场景下,TIRADS指南用于偶发甲状腺结节风险分层时可能以微弱优势较ATA2015更具成本效益。

研究设计与样本

  • 成本-效用分析,采用决策树模型,评估成人偶发甲状腺结节<4 cm患者。
  • 模型输入来自已发表文献、观察数据和专家意见。
  • 采用单支付方视角、加拿大元货币、5年时间跨度、50000加元支付意愿阈值、每年1.5%贴现率。
  • 进行了情景分析、确定性和概率敏感性分析。

诊断标准与关键数值

  • 主要结局为增量成本效益比(ICER),以每获得一个质量调整生命年(QALY)的增量成本表示。
  • 基础案例:TIRADS较ATA2015多获得0.005 QALY且少花费25加元,TIRADS微弱主导ATA2015。
  • 概率敏感性分析:TIRADS在79.7%的情况下是更具成本效益的选择。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 结果对活检恶性率以及良性结节、亚临床恶性或监测中患者的效用值敏感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Thyroid nodules are a common incidental imaging finding and prone to overdiagnosis. Several risk stratification systems have been developed to reduce unnecessary work-up, with two of the most utilized including the American Thyroid Association 2015 (ATA2015) and the newer American College of Radiology Thyroid Imaging, Reporting and Data System (TIRADS) guidelines. The purpose of this study is to evaluate the cost-effectiveness of the ATA2015 versus the TIRADS guidelines in the management of incidental thyroid nodules.

METHODS: A cost-utility analysis was conducted using decision tree modeling, evaluating adult patients with incidental thyroid nodules < 4 cm. Model inputs were populated using published literature, observational data, and expert opinion. Single-payer perspective, Canadian dollar currency, five-year time horizon, willingness to pay (WTP) threshold of $50,000, and discount rate of 1.5% per annum were utilized. Scenario, deterministic and probabilistic sensitivity analyses were performed. The primary outcome was the incremental cost-effectiveness ratio (ICER) expressed as incremental cost per quality-adjusted life year (QALY) gained.

RESULTS: For the base case scenario, TIRADS dominated the ATA2015 strategy by a slim margin, producing 0.005 more QALYs at $25 less cost. Results were sensitive to the malignancy rate of biopsy and the utilities of a patient with a benign nodule/subclinical malignancy or under surveillance. Probabilistic sensitivity analysis showed that TIRADS was the more cost-effective option 79.7% of the time.

CONCLUSION: The TIRADS guidelines may be the more cost-effective strategy by a small margin compared to ATA2015 in most scenarios when used to risk stratify incidental thyroid nodules.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Pang EH, Carter AW, Prisman E, et al. Cost-Effectiveness of the ACR TIRADS Compared to the ATA 2015 Risk Stratification Systems in the Evaluation of Incidental Thyroid Nodules. Acad Radiol. 2024. PMID: 38679528. doi:10.1016/j.acra.2024.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。